SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$15.48
Market Cap
$12.35B
52W High
$29.23
52W Low
$12.07
ADV30
6,223,146
Next earnings
2026-10-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -220,496,000 | -215,700,000 | 752,185,000 | 419,365,000 | 122,202,000 |
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
| Sep 2025 | 0 | — | -234,211,000 | -231,793,000 | 261,729,000 | 238,554,000 | 69,466,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-458,433,000
Investing CF
$-262,570,000
Financing CF
$842,509,000
CapEx
$-1,389,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-07-26
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,699,283,000
Inventory
—
Receivables
$557,000
ST Investments
$271,313,000
EBIT TTM
$-866,623,000
Pretax Income TTM
$-856,039,000
Interest Exp TTM
$0
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | 658,860,000 | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | 388,748,000 | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | 77,692,000 | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | 126,654,000 | -41,582,000 |
TTM Snapshot
Revenues TTM
$220,000
NetIncome TTM
$-161,820,000
OpCashFlow TTM
$0
Assets (Latest)
$751,182,000
Forward EPS
$-1.20
Max Pain — expiry 2026-10-02 (volume-derived — Yahoo OI feed degraded)
max pain strike: $16.00 · spot: $15.48 · call volume: 4,170 · put volume: 9,150
Expected Move to 2026-10-02:
±$3.75
(24.22%) —
implied range
$11.73 –
$19.23
· ATM straddle on $15.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.50B | $115.63 | — |
| AAVXF | Abivax S.A. | $12.13B | $139.00 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.95B | $517.04 | — |
| BBIO | BridgeBio Pharma, Inc. | $13.02B | $66.61 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.51B | $59.46 | — |
News headlines (Yahoo Finance, 1h cache)
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
2026-09-29 06:32 · Yahoo
SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare?
2026-09-28 23:35 · Yahoo
Summit Therapeutics Stock Surges After AstraZeneca Reveals $2 Billion Investment
2026-09-28 22:27 · Yahoo
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
2026-09-28 21:30 · Yahoo
Is Summit Therapeutics (SMMT) Below Fair Value On New Ivonescimab Survival Data?
2026-09-16 08:11 · Yahoo
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
2026-09-14 16:41 · Yahoo
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy
2026-09-09 14:07 · Yahoo
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
2026-09-09 01:32 · Yahoo
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
2026-09-07 05:53 · Yahoo
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
2026-09-03 20:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.